# Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers

> **NCT03849560** · PHASE2,PHASE3 · COMPLETED · sponsor: **NPO Petrovax** · enrollment: 612 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** Grippol® Quadri
- **BIOLOGICAL:** Grippol® Plus, trivalent (Yamagata lineage)
- **BIOLOGICAL:** Grippol® Plus, trivalent (Victoria lineage)

## Key facts

- **NCT ID:** NCT03849560
- **Lead sponsor:** NPO Petrovax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2017-06
- **Final completion:** 2017-08
- **Target enrollment:** 612 (ACTUAL)
- **Last updated:** 2024-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03849560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03849560, "Safety, Reactogenicity, Immunogenicity, Efficacy of Influenza Vaccines Grippol® Quadri and Grippol® Plus in Volunteers". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03849560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*